Japan Antibacterial (Antibiotics) Drugs Market Analysis Report 2022 to 2030

Japan Antibacterial (Antibiotics) Drugs Market Analysis

$ 3999

Japan Antibacterial (Antibiotics) Drugs Market is at around $3.16 Bn in 2023 and is projected to reach $4.36 Bn in 2030, exhibiting a CAGR of 4.7% during the forecast period. The market is growing as a result of the aging population, rising infectious disease prevalence, and technological advancements in antibiotics. The market is dominated by key players like Mitsubishi Chemical Group Corporation, Sumitomo Dainippon Pharma Co., Ltd., Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.

ID: IN10JPPH005 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Aneri Parekh

Buy Now

Japan Antibacterial (Antibiotics) Drugs Market Executive Summary

Japan Antibacterial (Antibiotics) Drugs Market is at around $3.16 Bn in 2023 and is projected to reach $4.36 Bn in 2030, exhibiting a CAGR of 4.7% during the forecast period.

The pharmaceutical industry in Japan is constantly changing, with a focus on developing new products to fight bacterial diseases. This market includes the manufacturing, distribution, and use of antibiotics that are specifically designed to meet the demands of the country's healthcare system. Japan's antibiotics market, which prioritizes innovation, regulatory compliance, and healthcare accessibility, is essential to the nation's progress in medical science and public health protection.

The antibiotics market in Japan is a thriving industry that has experienced notable expansion and innovation. Leading the way in the creation of innovative antibiotic therapies are Japanese pharmaceutical companies, that prioritize research and development. The market is expanding due to technological developments and regulatory backing, which satisfies the growing demand for antimicrobial treatments. Partnerships between government programs and industry players help to accelerate the market's progress in tackling healthcare issues and improving patient outcomes.

Recent years have seen a noticeable change in the antibiotic industry. The market reached $50.91 Bn in 2023 and is expected to propel further. Infectious diseases and new product inventions are the primary causes of this rise. These developments have also been facilitated by the need for more research and development, novel antimicrobial formulations, and antibiotic prescriptions. New antibiotic discoveries and urbanization have an impact on market expansion.

Mitsubishi Chemical Group Corporation holds a commanding 20% of the market in Japan for antibiotics. Their success is a result of their strong portfolio of antibiotics based on cephalosporins, their unwavering dedication to research and development, and their ongoing contributions to the field, which have cemented their leadership position in the sector.

Japan antibacterial (antibiotics) drugs market

Market Dynamics

Market Growth Drivers:

Infectious Diseases: Rising infectious disease levels drive the antibiotics industry. Due to urbanization, globalization, and increased travel, infectious diseases spread more easily, requiring antibiotics.

Aging Population: Japan has one of the fastest-aging populations. Older people's weakening immune systems make them more prone to illnesses, increasing antibiotics demand. There were 36.2 Mn senior citizens in Japan in 2023 who were 65 years of age or older.

Technological Advancements in Antibiotics: New antibiotics with higher efficacy and fewer adverse effects are introduced as antibiotic research and development progresses. These advances boost market growth by improving treatment alternatives.

Market Restraints:

Regulatory Hurdles: Japan has strict drug approval and price laws. These laws can take both time and resources for pharmaceutical companies, delaying the launch of new antibiotics or expansion of existing ones.

Competition from Generics: After antibiotic patents expire, generic alternatives enter the market, putting pressure on brand-name antibiotic prices and profit margins.

Treatments: With advances in medical technology, immunotherapies, and precision medicine are gaining popularity. Alternative antibiotics may reduce antibiotic use for some illnesses.

Healthcare Policies and Regulatory Landscape

The regulatory agency that works with the Ministry of Health, Labour, and Welfare in Japan is called the Pharmaceuticals and Medical Devices Agency (PMDA). The PMDA must receive the NDA dossier and the required funds. Upon examining the NDA dossier, the PMDA might ask for more information. If the PMDA approves the medicine with the NDA dossier, it will be authorized for sale in Japan. Japan's drug approval procedure is extremely stringent and comprehensive. An extensive assessment of the submitted New Drug Application (NDA) is required. This process ensures that only drugs meeting the highest quality standards may be sold, which increases the complexity of drug regulation in Japan.

Competitive Landscape

Key Players:

Mitsubishi Chemical Group Corporation
Sumitomo Dainippon Pharma Co., Ltd.
Pfizer Inc.
Roche
Novartis AG
GlaxoSmithKline plc
Abbott Laboratories
Johnson & Johnson
Merck & Co., Inc.
Sanofi S.A.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Antibacterial (Antibiotics) Drugs Market Segmentation

By Drug Class

Cephalosporins
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

By Type

Branded Antibiotics
Generic Antibiotics

By Action Mechanism

Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

By Spectrum

Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic

By Administration

Oral
Intravenous
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.